SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

This is a legacy token commemorating the pseudonym Satoshi Nakamoto.

Satoshi Nakamoto

Satoshi Nakamoto is trending as community members highlight the tokenization of the pseudonymous Bitcoin creator as a monumental narrative with limitless potential. Many believe that owning $SATOSHI is akin to owning a piece of crypto culture itself, and that it could become the 'Bitcoin of memes'. The community expresses strong conviction and excitement for its future.

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

Internet Computer (ICP) is trending as the community discusses its potential, noting a recent price pump and increased trading volume. Some speculate about the catalyst behind the movement, while others point to cross-chain analysis indicating potential whale accumulation. Despite the positive price action, skepticism remains due to ICP's past performance and concerns about its tokenomics.

Optimism is more than just a single blockchain – it's a growing network of chains called the Superchain, all built on the open-source OP Stack. While OP Mainnet was the first, many prominent chains now run on the Optimism’s OP Stack, including Base (by Coinbase), Unichain (by Uniswap), Ink (by Kraken), and World Chain (by Worldcoin). The OP Stack has become the leading framework for Ethereum Layer 2 chains, powering the majority of L2 activity today. Every OP Chain in the Superchain contributes back to the Optimism Collectiv and all chains follow a standardized revenue-sharing model: the greater of 2.5% of total chain revenue or 15% of onchain profit (defined as fees minus L1 gas costs) is paid back to the Optimism. By aligning economic incentives across many chains, Optimism transforms Ethereum scaling into a sustainable flywheel by delivering fast, low-cost transactions while reinvesting in the future of the ecosystem. OP holders participate in governance to shape protocol upgrades, funding decisions, and more.

Optimism Coin

Optimism Coin is trending as investors discuss its potential as a major retail squeeze candidate, while some traders are shorting, anticipating a collapse following the FOMC meeting. Community members are actively debating whether altcoins are dead while also assessing the impact of news such as the NEAR Foundation partnership on price movements.

zkSync

ZK is trending as community members discuss its potential, particularly after the delivery of Atlas. Bullish sentiment seems to be building, with some eyeing key resistance levels and anticipating further upside for the project. Recent developments around ZK-tech, enterprise solutions, and compiler updates are also driving interest.

Grindr, Inc. engages in the operation of a social media network application for the gay, bi, trans, queer, and other members of the LGBTQ+ community. The company was founded in 2009 and is headquartered in West Hollywood, CA.

Grindr Inc - Ordinary Shares - Class A

Grindr Inc

Grindr is trending due to buyout speculation, with major shareholders proposing a take-private deal at $18 per share, creating significant community buzz around a potential near-term return. Discussions also involve the possibility of short squeezes given the stock's high short interest. Some traders are weighing in on whether minority shareholders will get a fair deal.

Fox Corp. engages in providing television production and broadcasting services. It also provides news under the brands FOX News Media, FOX Sports, FOX Entertainment and FOX Television Stations, and Tubi Media Group. It operates through the following segments: Cable Network Programming, Television, and Other and Corporate. The Cable Network Programming segment refers to the production and licensing of news and sports content distributed primarily through traditional cable television systems, direct broadcast satellite operators, and telecommunication companies and online multi-channel video programming distributors. The Television segment focuses on the acquisition, marketing, and distribution of broadcast network programming. The Other and Corporate segment relates to the FOX Studio Lot, Credible Labs Inc, corporate overhead costs, and intracompany eliminations. The company was founded by Keith Rupert Murdoch on May 3, 2018, and is headquartered in New York, NY.

Fox Corporation - Ordinary Shares - Class B

Fox Corporation - Class B

FOX is trending due to a mix of factors, including discussions about potential retail squeezes and exclusive content partnerships by Tubi Media Group. Recent earnings exceeding expectations and analyst upgrades are contributing to the stock's momentum. Community members are also actively evaluating options strategies and discussing technical indicators, alongside broader debates about media bias.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Terns Pharmaceuticals Inc

TERN is trending as the community discusses its potential as a buyout candidate and strategic restructuring after a recent discontinuation of metabolic programs. Despite the setback in its obesity program, the stock price has seen improvement, leading to speculation about a potential acquisition or licensing deal. Investors are also monitoring upcoming trial data for its CML program as a key catalyst.

Peloton Interactive, Inc. provides an at-home fitness platform for live and on-demand indoor cycling classes. The firm pioneered connected, technology-enabled fitness, and the streaming of immersive, instructor-led boutique classes for its members. It operates through the Connected Fitness Products and Subscription segments. The Connected Fitness Products segment includes the sales of bikes, tread & related accessories. The Subscription segment refers to the monthly subscription and credits from live studio classes. The company was founded by John Foley, Graham Stanton, Thomas Cortese, Yony Feng, and Hisao Kushi in 2012 and is headquartered in New York, NY.

Peloton Interactive Inc - Ordinary Shares - Class A

Peloton Interactive Inc

Peloton is trending as analysts turn bullish following recent financial results and upgrades from Goldman Sachs and Macquarie, with community members discussing potential for a turnaround. Speculation includes possible AI integration and a potential short squeeze, with some comparing PTON's potential to Carvana's comeback. However, others remain skeptical, citing a challenging macroeconomic environment and past disappointments.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Harrow Health Inc

Harrow Health is trending due to community excitement around upcoming Q3 earnings and the company's potential to exceed consensus, with optimism fueled by positive outlooks on VEVYE and its market stabilization. Discussions also focus on Harrow's strategic moves, like new dry eye positions and long-term growth, with some debating the impact of IHEEZO sales and short-term market sentiment. Community members are sharing revenue estimates and roadmaps, with many confidently predicting substantial stock price appreciation in the coming months.

Zepp Health Corp. engages in the development of smart wearable health and consumer fitness devices. It empowers users to achieve their well-being goals by optimizing their health, fitness, and wellness journeys. Its brands include Amazfit, Zepp Clarity, and Zepp Aura. The company was founded by Huang Wang in 2013 and is headquartered in Gorinchem, Netherlands.

Zepp Health Corporation - ADR

Huami Corp

ZEPP is trending amid discussions about its potential as a leading AI wearables company and a "Garmin killer," with some anticipating strong growth and a short squeeze. Bullish sentiment is fueled by positive product reviews, rising demand, and strategic investments, while bears cite concerns about valuation and profitability, creating a volatile trading environment. Some analysts anticipate a strong Q3, which could drive the stock higher.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales

Alnylam's Q3 earnings and revenues surge past forecasts, powered by booming Amvuttra sales and a key milestone payment from Roche.

Compared to Estimates, Alnylam (ALNY) Q3 Earnings: A Look at Key Metrics

Although the revenue and EPS for Alnylam (ALNY) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top Estimates

Alnylam (ALNY) delivered earnings and revenue surprises of +73.65% and +22.25%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2025 and reviewed...

Zoetis Gears Up to Report Q3 Earnings: Here's What to Expect

ZTS is poised for another earnings beat as rising demand for companion animal products like Simparica Trio and Apoquel drives expected Q3 revenue growth.

Amgen's Q3 Earnings in the Cards: Here's What to Expect 

Amgen's Q3 results are on deck, with growth from newer drugs offset by biosimilar competition and pricing pressures.

Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?

Strong Trikafta/Kaftrio demand, along with contributions from Alyftrek, Casgevy and Journavx, may have helped VRTX outperform in the third quarter.

Exploring Analyst Estimates for Alnylam (ALNY) Q3 Earnings, Beyond Revenue and EPS

Evaluate the expected performance of Alnylam (ALNY) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

ANI Pharmaceuticals to Report Q3 Earnings: Is a Beat in the Cards?

ANIP's rising Cortrophin Gel sales and new rare disease products, along with generic and other segments, could power another earnings beat this quarter.

Krystal Biotech, Inc. (KRYS) Reports Next Week: Wall Street Expects Earnings Growth

Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Alnylam Pharmaceuticals Inc

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Palantir Technologies Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	$1.32	--	--	N/A
Q3 '25	$0.56	$1.84	228.01%	BEAT
Q2 '25	-$0.54	-$0.51	6.20%	BEAT
Q1 '25	-$0.89	-$0.44	50.56%	BEAT
Q4 '24	-$0.60	-$0.65	-9.17%	MISSED

ALNY
Alnylam Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest ALNY News

ALNYAlnylam Pharmaceuticals Inc